- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03020979
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
May 30, 2017 updated by: Qiong Wu, First Affiliated Hospital Bengbu Medical College
A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Apatinib in Patients With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer.
Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites.
Therefore, drugs such as apatinib that target angiogenesis may control the development of malignant ascites.
The study is to evaluate the efficacy and safety of apatinib in patients with refractory malignant ascites.
Study Overview
Detailed Description
The study is to investigate the efficacy and safety of apatinib in patients with refractory malignant ascites.
A total of 120 patients with performance status 0-2 were enrolled in this study and 500mg apatinib tablets were administered orally, once daily until disease progression or intolerable toxicity or patients withdrawal of consent.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Qiong Wu, M.D. Ph.D.
- Phone Number: +86-552-3074480
- Email: byzlnk@163.com
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China
- Recruiting
- Qiong Wu
-
Contact:
- Rui Wang, MD
- Phone Number: +86-0552-3074480
- Email: byzlnk@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Persistent or symptomatic ascites with positive cytology secondary to any histologically confirmed tumor type not amenable to cytoreductive surgery or additional chemotherapy
- Patients may enroll in this study irrespective of previous therapy including diuretics, surgery, chemotherapy, immunotherapy and radiation therapy
- Must have received a minimum of two paracentesis procedures and a trial of diuretic therapy within 60 days of study entry
- Age Restrictions: 18-75 years
- Life Expectancy: 12 weeks or more
- ECOG Performance Status: 0-2
- Able and willing to provide informed consent and comply with study and/or follow-up procedures
- Normal organ and marrow function as defined by: Leukocytes >/= 3,000/mcL; Absolute neutrophil count >/= 1,500/mcL; Platelets >/= 100,000/mcL; Total bilirubin within normal institutional limits; AST (SGOT)/ALT(SGPT) </= 2.5 X institutional upper limit of normal (ULN); Creatinine within normal institutional limits OR Creatinine clearance >/+ 60 mL/min for patients with creatinine levels above the institutional normal; Serum Potassium within normal institutional limits; Serum Sodium within normal institutional limits
Exclusion Criteria:
- Patients having received anti-angiogenic agents as part of the treatment of their malignancy within 60 days prior to study entry
- Current, recent (within 30 days of the first infusion of this study) or planned administration of chemotherapy (including all routes of administration), immunotherapy, biologic therapy, radiation therapy or any other anti-angiogenic therapy (e.g., bevacizumab, other tyrosine kinase inhibitors)
- Current, recent (within 30 days of the first infusion of this study), or planned participation in any other experimental drug study
- Pregnant women; A serum pregnancy test will be given to females of childbearing potential prior to study enrollment and the participant must agree to use adequate contraception (barrier or hormonal methods) prior to study entry and for the duration of study participation.
- Un-controlled hypertension (defined as systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg
- History of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Grade III or greater congestive heart failure
- History of myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months prior to study entry
- Known CNS disease, except for treated brain metastasis.
- Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to study entry
- History of gastrointestinal hemorrhage within 6 month prior to study entry
- Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study entry or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device or paracentesis/thoracentesis, within 7 days prior to study entry
- History of abdominal fistula or gastrointestinal perforation within 6 months prior to study entry
- Any bowel obstruction that has not fully recovered despite medical or surgical intervention prior to study entry
- Evidence of bowel wall thickening outside the site of the known primary malignancy on baseline radiographs
- Serious, non-healing wound, active ulcer, or untreated bone fracture
- Proteinuria as demonstrated by a Urine Protein/Creatinine ration >/= 1.0 at screening
- Known hypersensitivity to any component of apatinib.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 500mg apatinib
Patients will receive 500mg of apatinib tablet orally, once daily.
|
Patients will take 500mg apatinib daily orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The repeat paracentesis response rate (proportion of subjects who have a doubling of baseline time to repeat paracentesis)
Time Frame: 12 weeks after initiation of study treatment
|
12 weeks after initiation of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The time to the need for the first repeat abdominal paracentesis after the start of apatinib therapy as compared with historical control data.
Time Frame: 12 weeks after initiation of study treatment
|
12 weeks after initiation of study treatment
|
The mean number of paracentesis procedures required in each patient over the course of three months.
Time Frame: 12 weeks after the initiation of study treatment
|
12 weeks after the initiation of study treatment
|
The effect of apatinib therapy on quality of life in patients with malignant ascites by using EORTC QLQ-C30 V3.0.
Time Frame: 12 weeks after the initiation of study treatment
|
12 weeks after the initiation of study treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2017
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
January 10, 2017
First Submitted That Met QC Criteria
January 11, 2017
First Posted (Estimate)
January 13, 2017
Study Record Updates
Last Update Posted (Actual)
May 31, 2017
Last Update Submitted That Met QC Criteria
May 30, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BYEC20161201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Ascites
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Sichuan Clover Biopharmaceuticals, Inc.Completed
-
Sequana Medical N.V.CompletedMalignant AscitesGermany, Switzerland, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Terminated
-
Eastern Regional Medical CenterTerminatedMalignant AscitesUnited States
-
West China HospitalRecruiting
-
Sequana Medical N.V.Withdrawn
-
Hospital Universitario Virgen MacarenaDelos ClinicalUnknownMalignant Ascites
-
Hui ting Xu,MDUnknown
-
Baylor College of MedicineGenentech, Inc.Withdrawn
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Huazhong University of Science and TechnologyUnknown
-
The First Affiliated Hospital of Zhengzhou UniversityRecruitingEsophageal Cancer by AJCC V8 StageChina